PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
59.45%
Growth of 59.45% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
2402.78%
Cost growth of 2402.78% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
-53.84%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-73.33%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
128.48%
R&D change of 128.48% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-2.99%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
71.99%
Marketing expense change of 71.99% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
770.17%
Other expenses change of 770.17% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
11.13%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.00%. Jim Chanos would check for waste.
80.79%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.92%. Jim Chanos would check for waste.
68.97%
Interest expense change of 68.97% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-15.84%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 1.39%. Seth Klarman would investigate efficiency.
117.98%
EBITDA change of 117.98% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
726.73%
Margin change of 726.73% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-103.69%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-27.74%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
91.61%
Other expenses change of 91.61% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
143.88%
Income change of 143.88% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
52.95%
Margin change of 52.95% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
95.09%
Tax expense change of 95.09% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
153.01%
Income change of 153.01% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
58.67%
Margin change of 58.67% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
141.84%
EPS change of 141.84% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
141.84%
Diluted EPS change of 141.84% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
8.51%
Share count change of 8.51% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
8.22%
Diluted share change of 8.22% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.